SCHEMBL22276019

SCHEMBL22276019

CC(Cn1nc(-c2cccc3c2oc2ccccc23)c2c(N)ncnc21)c1n[nH]c2cc(-c3nn(C)c4ncnc(N)c34)ccc12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FYN P06241 8/20 0.45
PIK3CD O00329 11/20 0.45
PIK3CA P42336 10/20 0.45
PIK3CG P48736 10/20 0.45
PRKDC P78527 10/20 0.45
PIK3CB P42338 9/20 0.45
MTOR P42345 8/20 0.45
ABL1 P00519 7/20 0.45
EGFR P00533 6/20 0.45
HCK P08631 6/20 0.45
SRC P12931 6/20 0.45
KDR P35968 6/20 0.45
EPHB4 P54760 6/20 0.45
DDR1 Q08345 1/20 0.39
LYN P07948 1/20 0.38
BLK P51451 1/20 0.38
PI4KB Q9UBF8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128451 0.78 PIK3CD (0.53) FYNPIK3CDPIK3CAPIK3CGPRKDC
SCHEMBL129811 0.69 PIK3CD (0.63) PIK3CDPIK3CAPIK3CGPRKDCPIK3CB
SCHEMBL129826 0.69 PIK3CD (0.60) PIK3CDPIK3CAPIK3CGPRKDCPIK3CB
SCHEMBL29651581 0.66 PIK3CD (0.44) FYNPIK3CDPIK3CAPIK3CGPRKDC
SCHEMBL11009 0.66 PIK3CD (0.44) FYNPIK3CDPIK3CAPIK3CGPRKDC
SCHEMBL29651699 0.65 PIK3CD (0.51) PIK3CDPIK3CAPIK3CGPRKDCPIK3CB
SCHEMBL10943 0.65 PIK3CD (0.51) PIK3CDPIK3CAPIK3CGPRKDCPIK3CB
SCHEMBL13826047 0.64 PIK3CD (0.60) PIK3CDPIK3CAPIK3CGPRKDCPIK3CB
SCHEMBL3610512 0.64 SRC (1.00) PIK3CDPIK3CAPIK3CGPRKDCPIK3CB
SCHEMBL17725997 0.63 FYN (1.00) FYNPIK3CDPIK3CAPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB FYN 709/4885PIK3CD 70/4885PIK3CA 143/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A FYN 406/4885PIK3CD 103/4885PIK3CA 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.